Aviva
RGEN icon

Aviva’s Repligen RGEN Stock Holding History

Aviva’s Portfolio RGEN Stock Details RGEN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-32,275
Closed -$4.07M – 935
2024
Q2 		$4.07M Sell
32,275
-16,130
-33% -$2.53M 0.01% 522
2024
Q1 		$8.9M Buy
48,405
+23,362
+93% +$4.45M 0.03% 462
2023
Q4 		$4.5M Buy
+25,043
New +$3.9M 0.02% 522
2023
Q3 		– Sell
-5,595
Closed -$791K – 1011
2023
Q2 		$791K Buy
+5,595
New +$897K ﹤0.01% 845
2021
Q2 		– Sell
-6,307
Closed -$1.23M – 957
2021
Q1 		$1.23M Sell
6,307
-2,440
-28% -$500K 0.01% 810
2020
Q4 		$1.68M Sell
8,747
-7,093
-45% -$1.29M 0.01% 726
2020
Q3 		$2.34M Sell
15,840
-3,337
-17% -$477K 0.01% 660
2020
Q2 		$2.37M Sell
19,177
-19,049
-50% -$2.24M 0.01% 601
2020
Q1 		$3.69M Buy
38,226
+16,045
+72% +$1.55M 0.03% 541
2019
Q4 		$2.05M Buy
+22,181
New +$1.86M 0.01% 688

Other funds holding RGEN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $3.89B AUM 16.15% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Aviva's RGEN Position: Q3 2024 in Review

Aviva sold out of Repligen (RGEN) in Q3 2024, closing a stake of 32,275 shares — an estimated $4.07M sold.

Aviva first reported a position in RGEN in Q4 2019 and held it in 10 quarters. The position peaked at $8.9M in Q1 2024. 444 funds tracked by Wall St. Rank hold RGEN as of Q3 2024.

  • Aviva reported no remaining Repligen position as of Q3 2024 after selling out during the quarter.
  • Aviva sold 32,275 Repligen shares in Q3 2024, an estimated $4.07M.
  • Aviva first reported a position in Repligen in Q4 2019 and held it in 10 quarters.
  • Aviva's Repligen position peaked at $8.9M in Q1 2024.
  • 444 funds tracked by Wall St. Rank held Repligen as of Q3 2024.

Based on Aviva's 13F filing for Q3 2024, filed 14 Nov 2024.